Lilly East

Lilly E. currently serves as Vice President of Quantitative & Clinical Pharmacology, Biomarker, and DMPK at Sarepta Therapeutics since May 2020, having previously held the position of Executive Director and Senior Director in the same field. Lilly E. is also a member of the Board of Directors for the IQ Consortium since August 2024. Prior experience includes roles as Director of Clinical Pharmacology & Pharmacometrics at Sarepta Therapeutics from 2019 to 2020, Associate Director of Clinical Pharmacology and Pharmacometrics at Biogen from 2017 to 2019, and Associate Director of Quantitative Pharmacology & Pharmacometrics at Merck from 2013 to 2017. Earlier experience includes working as a Clinical Pharmacologist & DMPK at Alkermes from 2012 to 2013. Lilly E. is currently pursuing a course of study at MIT Sloan School of Management and holds a Bachelor's degree in Molecular Cell Biology and Biochemistry from the University of California, Berkeley, as well as a Ph.D. in Pharmaceutical Sciences from the University of Washington.